{"name":"Grupo Espanol de Tumores Neuroendocrinos","slug":"grupo-espanol-de-tumores-neuroendocrinos","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"177Lu-edotreotide","genericName":"177Lu-edotreotide","slug":"177lu-edotreotide","indication":"Neuroendocrine tumors (NET) expressing somatostatin receptors","status":"phase_3"},{"name":"STZ-5FU","genericName":"STZ-5FU","slug":"stz-5fu","indication":"Colorectal cancer","status":"phase_3"},{"name":"Drug: Everolimus","genericName":"Drug: Everolimus","slug":"drug-everolimus","indication":"Neuroendocrine tumors (pancreatic and non-pancreatic)","status":"phase_3"}]}],"pipeline":[{"name":"177Lu-edotreotide","genericName":"177Lu-edotreotide","slug":"177lu-edotreotide","phase":"phase_3","mechanism":"177Lu-edotreotide is a radioligand therapeutic that binds to somatostatin receptor 2 (SSTR2) on neuroendocrine tumor cells and delivers targeted radiation to kill them.","indications":["Neuroendocrine tumors (NET) expressing somatostatin receptors","Gastroenteropancreatic neuroendocrine tumors (GEP-NET)"],"catalyst":""},{"name":"STZ-5FU","genericName":"STZ-5FU","slug":"stz-5fu","phase":"phase_3","mechanism":"STZ-5FU is a chemotherapeutic agent that works by interfering with DNA synthesis.","indications":["Colorectal cancer","Breast cancer"],"catalyst":""},{"name":"Drug: Everolimus","genericName":"Drug: Everolimus","slug":"drug-everolimus","phase":"phase_3","mechanism":"Everolimus inhibits mTOR (mammalian target of rapamycin), a key protein kinase that regulates cell growth and proliferation.","indications":["Neuroendocrine tumors (pancreatic and non-pancreatic)","Advanced renal cell carcinoma","Breast cancer (hormone receptor positive)"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":3,"phaseCounts":{"phase_3":3},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}